Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience

Basit Öğe Kaydı
dc.authoridFerhatoglu, Ferhat/0000-0002-7651-6789
dc.authoridGokmen, Erhan/0000-0003-4596-2986
dc.authoridŞahin, Ahmet Bilgehan/0000-0002-7846-0870
dc.authoridKaraçin, Cengiz/0000-0002-7310-9328
dc.authoridBulut, Gülcan/0000-0001-7382-0972
dc.authoridPaydas, Semra/0000-0003-4642-3693
dc.authoridAk, Naziye/0000-0001-5790-7066
dc.authorwosidFerhatoglu, Ferhat/AAT-5977-2021
dc.authorwosidGokmen, Erhan/HKE-3549-2023
dc.authorwosidDOGAN, MUTLU/GNP-7311-2022
dc.authorwosidŞahin, Ahmet Bilgehan/AAM-4927-2020
dc.authorwosidKaraçin, Cengiz/ABB-3650-2020
dc.authorwosidBulut, Gülcan/AAH-8257-2021
dc.authorwosidPaydas, Semra/F-3132-2018
dc.contributor.authorBahceci, Aykut
dc.contributor.authorPaydas, Semra
dc.contributor.authorAk, Naziye
dc.contributor.authorFerhatoglu, Ferhat
dc.contributor.authorSaip, Pinar Mualla
dc.contributor.authorSeydaoglu, Gulsah
dc.contributor.authorBilici, Mehmet
dc.date.accessioned2024-06-12T11:08:24Z
dc.date.available2024-06-12T11:08:24Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractAim The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) in different lines of treatment. Method Retrospective analysis of T-DM1 results of human epidermal growth factor receptor 2 (Her2) positive 414 cases with mBC from 31 centers in Turkey. Findings Except 2, all of the cases were female with a median age of 47. T-DM1 had been used as second-line therapy in 37.7% of the cases and the median number of T-DM1 cycles was 9. Progression-free survival (PFS) and overall survival (OS) times were different according to the line of treatment. The median OS was found as 43, 41, 46, 23 and 17 months for 1st, 2nd, 3rd, 4th and 5th line, respectively (p = 0.032) while the median PFS was found as 37, 12, 8, 8 and 8 months, respectively (p = 0.0001). Treatment was well tolerated by the patients. The most common grade 3-4 adverse effects were thrombocytopenia (2.7%) and increased serum gamma-glutamyl transferase (2%). Discussion The best of our knowledge this is the largest real-life experience about the safety and efficacy of T-DM1 use in cases with mBC after progression of Her2 targeted treatment. This study suggests and supports that T-DM1 is more effective in earlier lines of treatment and is a reliable option for mBC.en_US
dc.identifier.doi10.1080/07357907.2021.1933011
dc.identifier.endpage481en_US
dc.identifier.issn0735-7907
dc.identifier.issn1532-4192
dc.identifier.issue6-7en_US
dc.identifier.pmid34014777en_US
dc.identifier.scopus2-s2.0-85107585337en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage473en_US
dc.identifier.urihttps://doi.org/10.1080/07357907.2021.1933011
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22421
dc.identifier.volume39en_US
dc.identifier.wosWOS:000658617100001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofCancer Investigationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMetastatic Breast Canceren_US
dc.subjectT-DM1en_US
dc.subjectEfficacyen_US
dc.subjectToxicityen_US
dc.subjectReal-World Experienceen_US
dc.subjectSurvivalen_US
dc.subjectReceptoren_US
dc.titleEfficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu